Contributions
Abstract: P1050
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. It is well known that patients with MS frequently report poor sleep and sleep disturbances more often than the general population, which may have a potentially important impact on overall health and quality of life.
Objectives: Our aim was to study the prevalence of sleep disturbance in patients with MS and to evaluate daytime sleepiness in a population of Portuguese patients using self-rated questionnaires.
Methods: Transversal, single-center study, recruiting consecutive MS patients attending between September and December 2017. Patients were analyzed in both their clinical features (type of MS, disease duration, clinical severity, underlying disease modifying treatment, concomitant antidepressant use and reported fatigue) and specific scales scores such as Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI). Antidepressants use and reported fatigue were obtained from clinical records.
Results: Forty-eight patients were included, 66.7% females. Mean age and mean disease duration were 41.7 years and 8.6 years, respectively. Mean Expanded Disability Status Scale was 1.74±1.8. Ten patients (20.8%) were treated with antidepressant drugs and 12 patients (25.0%) reported fatigue. As concerns sleep evaluations, mean PSQI was 6.8±4.4 (25 patients [52.1%] above the cut-off value >5); ESS score was 7.7±4.0 (17 patients [35.4%] above the cut-off value >=10) and ISI score was 9.6±6.3 (29 patients [69.4%] above the cut-off value >=8).
Conclusions: Our results suggest that MS is associated with a high prevalence of sleep complaints, including subjective poor sleep quality, excessive daytime sleepiness and insomnia. These results raise the suggestion that clinicians should actively and routinely ask about sleep when delineating a comprehensive care plan for patients with MS. Further large-scale evaluations are needed to define the extent to which sleep disorders affect MS population and to understand the relationship between those disorders, the underlying mechanisms and consequences.
Disclosure: Rui Pedrosa served as an advisor or consultant for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and Bayer. Carlos Capela served as an advisor or consultant for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. João Sequeira has received compensation for serving as speaker from Novartis. Ary de Sousa has received compensation for serving as speaker from Novartis. Marisa Brum has received compensation for serving as speaker from Biogen, Merck and Sanofi-Genzyme. Ariana Barros: nothing to disclose. Joana Parra: nothing to disclose.
Abstract: P1050
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. It is well known that patients with MS frequently report poor sleep and sleep disturbances more often than the general population, which may have a potentially important impact on overall health and quality of life.
Objectives: Our aim was to study the prevalence of sleep disturbance in patients with MS and to evaluate daytime sleepiness in a population of Portuguese patients using self-rated questionnaires.
Methods: Transversal, single-center study, recruiting consecutive MS patients attending between September and December 2017. Patients were analyzed in both their clinical features (type of MS, disease duration, clinical severity, underlying disease modifying treatment, concomitant antidepressant use and reported fatigue) and specific scales scores such as Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS) and Insomnia Severity Index (ISI). Antidepressants use and reported fatigue were obtained from clinical records.
Results: Forty-eight patients were included, 66.7% females. Mean age and mean disease duration were 41.7 years and 8.6 years, respectively. Mean Expanded Disability Status Scale was 1.74±1.8. Ten patients (20.8%) were treated with antidepressant drugs and 12 patients (25.0%) reported fatigue. As concerns sleep evaluations, mean PSQI was 6.8±4.4 (25 patients [52.1%] above the cut-off value >5); ESS score was 7.7±4.0 (17 patients [35.4%] above the cut-off value >=10) and ISI score was 9.6±6.3 (29 patients [69.4%] above the cut-off value >=8).
Conclusions: Our results suggest that MS is associated with a high prevalence of sleep complaints, including subjective poor sleep quality, excessive daytime sleepiness and insomnia. These results raise the suggestion that clinicians should actively and routinely ask about sleep when delineating a comprehensive care plan for patients with MS. Further large-scale evaluations are needed to define the extent to which sleep disorders affect MS population and to understand the relationship between those disorders, the underlying mechanisms and consequences.
Disclosure: Rui Pedrosa served as an advisor or consultant for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva and Bayer. Carlos Capela served as an advisor or consultant for Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. João Sequeira has received compensation for serving as speaker from Novartis. Ary de Sousa has received compensation for serving as speaker from Novartis. Marisa Brum has received compensation for serving as speaker from Biogen, Merck and Sanofi-Genzyme. Ariana Barros: nothing to disclose. Joana Parra: nothing to disclose.